Anika Therapeutics stockholders approve 475,000-share increase in incentive plan

Anika Therapeutics, Inc.

Share reserve under 2017 Omnibus Incentive Plan raised from 5,285,000 to 5,760,000.
All three Class II director nominees elected: Blanchard, Capper, Larsen.
Advisory say-on-pay vote passed with 8,374,076 for vs 2,529,081 against.
Deloitte & Touche ratified as independent auditor for fiscal 2025.
Annual meeting had 86.13% of voting power present; no opposition to board's solicitation.

item 5.02item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.